ArticleRadiation research2018
Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency: Lessons Learned from Biological Threats and other Disease Treatments.
Article in Radiation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Breaking through the radiation dilemma: development and clinical translation of anti-radiation drugs.Pharmaceutical science advances · 2026Review
- Radiation emergency medical countermeasures: Current formulary, identified gaps, and future approaches.Animal models and experimental medicine · 2025Review
- Anti-Ceramide ScFv Prophylaxis for First Responders to a Limited Nuclear Attack.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2024Article
- An Overview of Radiation Countermeasure Development in Radiation Research from 1954 to 2024.Radiation research · 2024Review
- Radiation and Chemical Program Research for Multi-Utility and Repurposed Countermeasures: A US Department of Health and Human Services Agencies Perspective.Disaster medicine and public health preparedness · 2024Article
- Effects of combined ciprofloxacin and Neulasta therapy on intestinal pathology and gut microbiota after high-dose irradiation in mice.Frontiers in public health · 2024Article
- Overlapping Science in Radiation and Sulfur Mustard Exposures of Skin and Lung: Consideration of Models, Mechanisms, Organ Systems, and Medical Countermeasures: Overlapping science in radiation and sulfur mustard injuries to lung and skin.Disaster medicine and public health preparedness · 2023Article
- The gut microbiome changes in wild type and IL-18 knockout mice after 9.0 Gy total body irradiation.Animal microbiome · 2023Article
- Development of radiation countermeasure agents for acute radiation syndromes.Animal models and experimental medicine · 2023Review
- Considerations of Medical Preparedness to Assess and Treat Various Populations During a Radiation Public Health Emergency.Radiation research · 2023Review
- A Review of Radiation-Induced Alterations of Multi-Omic Profiles, Radiation Injury Biomarkers, and Countermeasures.Radiation research · 2023Review
- Inter-agency perspective: Translating advances in biomarker discovery and medical countermeasures development between terrestrial and space radiation environments.Life sciences in space research · 2022Article
- Comparison of Proteomic Expression Profiles after Radiation Exposure across Four Different Species.Radiation research · 2022Article
- United States medical preparedness for nuclear and radiological emergencies.Journal of radiological protection : official journal of the Society for Radiological Protection · 2021Article
- Challenges and Strategies in the Development of Radiation Biodosimetry Tests for Patient Management.Radiation research · 2021Review
- Scientific research and product development in the United States to address injuries from a radiation public health emergency.Journal of radiation research · 2021Article
- Anti-ceramide single-chain variable fragment mitigates radiation GI syndrome mortality independent of DNA repair.JCI insight · 2021Article
- Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.Frontiers in pharmacology · 2021Review
- Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities.Frontiers in pharmacology · 2021Article
- IL-18 binding protein (IL-18BP) as a novel radiation countermeasure after radiation exposure in mice.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
The risk of a radiological or nuclear public health emergency is a major growing concern of the U.S. government. To address a potential incident and ensure that the government is prepared to respond to any subsequent civilian or military casualties, the U.S. Department of Health and Human Services and the Department of Defense have been charged with the development of medical countermeasures (MCMs) to treat the acute and delayed injuries that can result from radiation exposure. Because of the limited budgets in research and development and the high costs associated with bring promising approaches from the bench through advanced product development activities, and ultimately, to regulatory approval, the U.S. government places a priority on repurposing products for which there already exists relevant safety and other important information concerning their use in humans. Generating human data can be a costly and time-consuming process; therefore, the U.S. government has interest in drugs for which such relevant information has been established (e.g., products for another indication), and in determining if they could be repurposed for use as MCMs to treat radiation injuries as well as chemical and biological insults. To explore these possibilities, the National Institute of Allergy and Infectious Diseases (NIAID) convened a workshop including U.S. government, industry and academic subject matter experts, to discuss the challenges and benefits of repurposing products for a radiation indication. Topics covered included a discussion of U.S. government efforts (e.g. funding, stockpiling and making products available for study), as well unique regulatory and other challenges faced when repurposing patent protected or generic drugs. Other discussions involved lessons learned from industry on repurposing pre-license, pipeline products within drug development portfolios. This report reviews the information presented, as well as an overview of discussions from the meeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.